Trinity Life Sciences, a healthcare-focused consulting firm, announced Wednesday that it has promoted Leslie Orne to lead as its CEO.
Orne, who currently serves as president and chief commercial officer at Trinity, will succeed outgoing CEO David Fitzhenry effective July 1.
Fitzhenry, who was at Trinity for 26 years, will remain close to the company, serving as a strategic advisor and member of the board of directors after he leaves the C-suite in the summer.
“Leslie will usher in an even more innovative era for the Company, demonstrating to life science clients the true power of using insights and analytics to revolutionize the commercial model,” said Matt Jennings, chairman of Trinity’s board of directors, in a statement. “In addition, we would like to extend a heartfelt thank you to David Fitzhenry for his enterprising and magnanimous leadership. He has built amazing teams, a strong culture and a truly differentiated offering that has set up Trinity for great success for many years to come.”
An industry veteran with more than 20 years of experience, Orne has overseen the “delivery of integrated consulting, insights and analytics services” to the firm’s clients since 2001.
Orne is also a member of Trinity’s board and played a key role in its recent acquisitions of BluePrint Research Group, CBPartners and D Cube Analytics. She also led its strategic partnerships with Bain & Co. as well as Havas Health & You.
Announced at the J.P. Morgan Healthcare Conference in January, the partnership between HH&Y and Trinity will allow both firms to “offer cohesive end-to-end commercial solutions to the life sciences industry.” HH&Y also took a minority stake in Trinity as part of the deal.
Looking forward, Orne will be tasked with continuing the growth plans for Trinity and expanding the brand’s presence.
“Trinity’s vision, mission and values are extremely important to me, and none of that will change,” Orne said in a statement. “Someday we or someone we love will be patients. I’m committed to the urgent pursuit of progress so that we can help our clients bring life-changing treatments to patients faster and more efficiently.”
